Cargando…
Oligomeropathies, inflammation and prion protein binding
The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445368/ https://www.ncbi.nlm.nih.gov/pubmed/36081661 http://dx.doi.org/10.3389/fnins.2022.822420 |
_version_ | 1784783406163296256 |
---|---|
author | Forloni, Gianluigi La Vitola, Pietro Balducci, Claudia |
author_facet | Forloni, Gianluigi La Vitola, Pietro Balducci, Claudia |
author_sort | Forloni, Gianluigi |
collection | PubMed |
description | The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies to define the common mechanism of action of protein misfolding diseases like Alzheimer, Parkinson or prion diseases. Using simple experimental conditions, with direct application of synthetic β amyloid or α-synuclein oligomers intraventricularly at micromolar concentrations, we could detect differences and similarities in the biological consequences. The two oligomer species affected cognitive behavior, neuronal dysfunction and cerebral inflammatory reactions with distinct mechanisms. In these experimental conditions the proposed mediatory role of cellular prion protein in oligomer activities was not confirmed. Together with oligomers, inflammation at different levels can be important early in neurodegenerative disorders; both β amyloid and α-synuclein oligomers induce inflammation and its control strongly affects neuronal dysfunction. This review summarizes our studies with β-amyloid or α-synuclein oligomers, also considering the potential curative role of doxycycline, a well-known antibiotic with anti-amyloidogenic and anti-inflammatory activities. These actions are analyzed in terms of the therapeutic prospects. |
format | Online Article Text |
id | pubmed-9445368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94453682022-09-07 Oligomeropathies, inflammation and prion protein binding Forloni, Gianluigi La Vitola, Pietro Balducci, Claudia Front Neurosci Neuroscience The central role of oligomers, small soluble aggregates of misfolded proteins, in the pathogenesis of neurodegenerative disorders is recognized in numerous experimental conditions and is compatible with clinical evidence. To underline this concept, some years ago we coined the term oligomeropathies to define the common mechanism of action of protein misfolding diseases like Alzheimer, Parkinson or prion diseases. Using simple experimental conditions, with direct application of synthetic β amyloid or α-synuclein oligomers intraventricularly at micromolar concentrations, we could detect differences and similarities in the biological consequences. The two oligomer species affected cognitive behavior, neuronal dysfunction and cerebral inflammatory reactions with distinct mechanisms. In these experimental conditions the proposed mediatory role of cellular prion protein in oligomer activities was not confirmed. Together with oligomers, inflammation at different levels can be important early in neurodegenerative disorders; both β amyloid and α-synuclein oligomers induce inflammation and its control strongly affects neuronal dysfunction. This review summarizes our studies with β-amyloid or α-synuclein oligomers, also considering the potential curative role of doxycycline, a well-known antibiotic with anti-amyloidogenic and anti-inflammatory activities. These actions are analyzed in terms of the therapeutic prospects. Frontiers Media S.A. 2022-08-23 /pmc/articles/PMC9445368/ /pubmed/36081661 http://dx.doi.org/10.3389/fnins.2022.822420 Text en Copyright © 2022 Forloni, La Vitola and Balducci. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Forloni, Gianluigi La Vitola, Pietro Balducci, Claudia Oligomeropathies, inflammation and prion protein binding |
title | Oligomeropathies, inflammation and prion protein binding |
title_full | Oligomeropathies, inflammation and prion protein binding |
title_fullStr | Oligomeropathies, inflammation and prion protein binding |
title_full_unstemmed | Oligomeropathies, inflammation and prion protein binding |
title_short | Oligomeropathies, inflammation and prion protein binding |
title_sort | oligomeropathies, inflammation and prion protein binding |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445368/ https://www.ncbi.nlm.nih.gov/pubmed/36081661 http://dx.doi.org/10.3389/fnins.2022.822420 |
work_keys_str_mv | AT forlonigianluigi oligomeropathiesinflammationandprionproteinbinding AT lavitolapietro oligomeropathiesinflammationandprionproteinbinding AT balducciclaudia oligomeropathiesinflammationandprionproteinbinding |